Frances Emms

Statistics

Publications

Citations

1.3K

H-Index

Active since

1992

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (UK) Limited (United Kingdom)

Frances Emms is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, ligand binding, and dopaminergic pharmacology.

Publications per year

1992–1999

Publications

3-[[4-(4-Chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine: An Antagonist with High Affinity and Selectivity for the Human Dopamine D4 Receptor

Janusz J. Kulagowski, Howard B. Broughton, Neil R. Curtis et al. · Journal of Medicinal Chemistry · 1996 · 257 citations · Full text

Medicine, Pharmacology, Neurochemistry +4

Expression and pharmacological characterization of the human D3 dopamine receptor.

Stephen B. Freedman, Shil Patel, R. Marwood et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 224 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +12

Biological Profile of L-745,870, a Selective Antagonist with High Affinity for the Dopamine D4 Receptor

Smita S. Patel, Stephen B. Freedman, Kerry L. Chapman et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 166 citations

Medicine, Medicinal Chemistry, Pharmacology +17

5-(4-Chlorophenyl)-4-methyl-3-(1-(2- phenylethyl)piperidin-4-yl)isoxazole: A Potent, Selective Antagonist at Human Cloned Dopamine D4 Receptors

Michael Rowley, Howard B. Broughton, Ian Collins et al. · Journal of Medicinal Chemistry · 1996 · 115 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Antagonism of the effects of (+)‐PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2receptor antagonist L‐741,626

B.J. Bowery, Z. Razzaque, Frances Emms et al. · British Journal of Pharmacology · 1996 · 58 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

1–5 of 17